Genitourinary Cancer: Updates on Treatments and Their Impact on the Kidney

Paloma Orozco Scott; Priya Deshpande; Matthew Abramson

doi:10.1016/j.semnephrol.2023.151344

Genitourinary Cancer: Updates on Treatments and Their Impact on the Kidney

Semin Nephrol. 2022 Nov;42(6):151344. doi: 10.1016/j.semnephrol.2023.151344. Epub 2023 May 10.

Authors

Paloma Orozco Scott¹, Priya Deshpande², Matthew Abramson²

Affiliations

¹ Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Medical School, New York, NY. Electronic address: paloma.orozcoscott@icahn.mssm.edu.
² Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

PMID: 37172546
DOI: 10.1016/j.semnephrol.2023.151344

Abstract

Genitourinary cancers are diverse in their presentation, prevalence, and mortality risk. Although there have been significant advancements in medical (eg, immune checkpoint inhibitors and tyrosine kinase inhibitors) and surgical treatments of genitourinary cancers, patients are still at risk for chronic kidney disease, hypertension, and electrolyte derangements in the short and long term. In addition, pre-existing kidney disease may increase the risk of developing some genitourinary cancers. This review focuses on the kidney-related effects of treatments for renal cell carcinoma and bladder and prostate cancers.

Keywords: Genitourinary cancer; bladder; immune checkpoint inhibitor; kidney; prostate; tyrosine kinase inhibitor.

Publication types

Review

MeSH terms

Carcinoma, Renal Cell* / epidemiology
Carcinoma, Renal Cell* / therapy
Humans
Kidney / pathology
Kidney Neoplasms* / pathology
Kidney Neoplasms* / therapy
Male
Prostatic Neoplasms* / pathology
Prostatic Neoplasms* / therapy
Urogenital Neoplasms* / therapy